MCID: DBT010
MIFTS: 56

Diabetic Neuropathy

Categories: Blood diseases, Eye diseases, Neuronal diseases

Aliases & Classifications for Diabetic Neuropathy

MalaCards integrated aliases for Diabetic Neuropathy:

Name: Diabetic Neuropathy 12 75 54 37 15 38 17
Diabetic Neuropathies 55 72

Classifications:



External Ids:

Disease Ontology 12 DOID:9743
KEGG 37 H01459
ICD9CM 35 250.6
MeSH 44 D003929
NCIt 50 C26748
SNOMED-CT 68 866003
UMLS 72 C0011882

Summaries for Diabetic Neuropathy

NINDS : 54 Diabetic neuropathy is a peripheral nerve disorder caused by diabetes or poor blood sugar control. The most common types of diabetic neuropathy result in problems with sensation in the feet. It can develop slowly after many years of diabetes or may occur early in the disease. The symptoms are numbness, pain, or tingling in the feet or lower legs. The pain can be intense and require treatment to relieve the discomfort. The loss of sensation in the feet may also increase the possibility that foot injuries will go unnoticed and develop into ulcers or lesions that become infected. In some cases, diabetic neuropathy can be associated with difficulty walking and some weakness in the foot muscles. There are other types of diabetic-related neuropathies that affect specific parts of the body. For example, diabetic amyotrophy causes pain, weakness and wasting of the thigh muscles, or cranial nerve infarcts that may result in double vision, a drooping eyelid, or dizziness. Diabetes can also affect the autonomic nerves that control blood pressure, the digestive tract, bladder function, and sexual organs. Problems with the autonomic nerves may cause lightheadedness, indigestion, diarrhea or constipation, difficulty with bladder control, and impotence.

MalaCards based summary : Diabetic Neuropathy, also known as diabetic neuropathies, is related to microvascular complications of diabetes 1 and diabetic autonomic neuropathy, and has symptoms including sciatica and neuralgia. An important gene associated with Diabetic Neuropathy is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are AGE-RAGE signaling pathway in diabetic complications and p70S6K Signaling. The drugs Nitric Oxide and Isosorbide Dinitrate have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and spinal cord, and related phenotypes are behavior/neurological and homeostasis/metabolism

KEGG : 37
Diabetic neuropathies (DNs) are nerve damaging disorders caused by diabetes. Diabetic neuropathy broadly comprise generalized symmetric polyneuropathies (acute sensory, chronic sensorimotor, autonomic) and asymmetric (focal and multifocal) neuropathies (cranial, truncal, focal-limb, proximal-motor, coexisting chronic inflammatory demyelinating), which affect all organs and system. Of all types, diabetic sensorimotor polyneuropathy (DSPN), also called distal symmetric neuropathy, is the most typical form. Typical Symptoms vary from person to person, but may include numbness, tingling, pain, or weakness that typically starts in the feet and progresses up the legs. This pattern of neuropathy shows a progressive distal axonopathy. It has been reported that vascular endothelial growth factor A is associated with DNs development and progression.

Wikipedia : 75 Diabetic neuropathies are nerve damaging disorders associated with diabetes mellitus. These conditions... more...

Related Diseases for Diabetic Neuropathy

Diseases related to Diabetic Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 304)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 33.5 VEGFA NTF3 INS AKR1B1
2 diabetic autonomic neuropathy 32.7 NTF3 NGF INS EPO AKR1B1
3 microvascular complications of diabetes 5 31.8 VEGFA PRKCB INS AKR1B1 AGER ACE
4 polyneuropathy 31.8 PMP22 MPZ AKR1B1
5 neuropathy 31.7 SCN9A PMP22 NGF MPZ
6 vascular disease 30.8 VEGFA INS AGER ACE
7 diabetic polyneuropathy 30.8 VEGFA SOD2 NTF3 NGF AKR1B1 AGER
8 carpal tunnel syndrome 30.7 VEGFA PMP22 INS
9 wallerian degeneration 30.3 VEGFA MPZ CNTF
10 diabetic angiopathy 30.2 SOD2 INS AGER
11 algoneurodystrophy 30.1 NGF CALCA
12 ischemia 30.0 VEGFA TRPV1 SOD2 EPO ACE
13 autonomic neuropathy 29.9 SCN9A NTRK1 NGF INS AKR1B1
14 burning mouth syndrome 29.9 TRPV1 SCN9A NGF
15 peripheral nervous system disease 29.9 TRPV1 SCN9A PMP22 NGF MPZ INS
16 arteries, anomalies of 29.8 VEGFA TRPV1 INS ACE
17 diabetes mellitus 29.8 VEGFA SOD2 INS EPO AKR1B1 AGER
18 paine syndrome 29.7 TRPV1 SCN9A NGF
19 kidney disease 29.6 INS EPO AKR1B1 AGER ACE
20 diabetic encephalopathy 29.1 INS GLO1
21 sensory peripheral neuropathy 29.1 TRPV1 PMP22 NTRK1 NTF3 NGF MPZ
22 diabetes mellitus, insulin-dependent 11.5
23 microvascular complications of diabetes 3 11.5
24 microvascular complications of diabetes 4 11.5
25 microvascular complications of diabetes 6 11.5
26 microvascular complications of diabetes 7 11.5
27 diabetes mellitus, noninsulin-dependent 11.5
28 microvascular complications of diabetes 2 11.4
29 abducens nerve disease 11.1
30 argyll robertson pupil 11.1
31 fainting 11.1
32 syncope 11.1
33 hyperglycemia 10.8
34 hypertensive encephalopathy 10.6 EPO ACE
35 severe nonproliferative diabetic retinopathy 10.6 VEGFA INS
36 renal artery disease 10.5 EPO ACE
37 lesion of sciatic nerve 10.5 TRPV1 NGF
38 hypoglycemic coma 10.5 VEGFA NTF3 INS
39 opiate dependence 10.4 VEGFA TRPV1 NGF
40 cough variant asthma 10.4 TRPV1 NGF
41 adenomyosis 10.4 VEGFA TRPV1 NGF
42 mononeuritis of lower limb 10.4 TRPV1 PMP22
43 mononeuropathy 10.4
44 autonomic dysfunction 10.4
45 gonadal disease 10.4 VEGFA PARP1 INS
46 charcot-marie-tooth hereditary neuropathy 10.4 PMP22 MPZ
47 female reproductive system disease 10.4 VEGFA TRPV1 PARP1
48 reproductive system disease 10.4 VEGFA TRPV1 PARP1
49 chronic pain 10.3
50 lipid metabolism disorder 10.3

Graphical network of the top 20 diseases related to Diabetic Neuropathy:



Diseases related to Diabetic Neuropathy

Symptoms & Phenotypes for Diabetic Neuropathy

UMLS symptoms related to Diabetic Neuropathy:


sciatica, neuralgia

MGI Mouse Phenotypes related to Diabetic Neuropathy:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.45 ACE AGER AKR1B1 CNTF INS MPZ
2 homeostasis/metabolism MP:0005376 10.38 ACE AGER AKR1B1 CNTF EPO GLO1
3 growth/size/body region MP:0005378 10.32 ACE AGER AKR1B1 INS NGF NTF3
4 immune system MP:0005387 10.27 ACE AGER CNTF EPO INS MPZ
5 cardiovascular system MP:0005385 10.24 ACE AGER EPO INS NGF NTF3
6 hematopoietic system MP:0005397 10.24 ACE AGER CNTF EPO INS MPZ
7 cellular MP:0005384 10.22 AGER CNTF EPO INS MPZ PARP1
8 mortality/aging MP:0010768 10.22 ACE AKR1B1 EPO INS MPZ NGF
9 integument MP:0010771 10.13 AGER EPO INS NGF NTRK1 PARP1
10 nervous system MP:0003631 10.13 CNTF INS MPZ NGF NTF3 NTRK1
11 muscle MP:0005369 10.07 AGER CNTF EPO INS NGF NTF3
12 no phenotypic analysis MP:0003012 9.8 CNTF INS NGF NTRK1 PARP1 TRPV1
13 normal MP:0002873 9.76 AGER EPO INS NGF NTF3 NTRK1
14 renal/urinary system MP:0005367 9.61 ACE AGER AKR1B1 INS PARP1 SCN9A
15 vision/eye MP:0005391 9.28 AKR1B1 INS NGF NTF3 NTRK1 PARP1

Drugs & Therapeutics for Diabetic Neuropathy

Drugs for Diabetic Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 339)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitric Oxide Approved Phase 4 10102-43-9 145068
2
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
3
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
4
tannic acid Approved Phase 4 1401-55-4
5
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
6
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
7
Histamine Approved, Investigational Phase 4 51-45-6 774
8
Amitriptyline Approved Phase 4 50-48-6 2160
9
Acetaminophen Approved Phase 4 103-90-2 1983
10
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
11
leucovorin Approved Phase 4 58-05-9 143 6006
12
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
13
Sodium citrate Approved, Investigational Phase 4 68-04-2
14
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
15
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
16
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
17
Metformin Approved Phase 4 657-24-9 4091 14219
18
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
19
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
20
Cetirizine Approved Phase 4 83881-51-0 2678
21
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
22
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
23
Linaclotide Approved Phase 4 851199-59-2 65351
24
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
25
Donepezil Approved Phase 4 120014-06-4 3152
26
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
27
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
28
Pyridoxal Phosphate Approved, Investigational, Nutraceutical Phase 4 54-47-7 1051
29
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
30
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
31
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
32
Cobalamin Experimental Phase 4 13408-78-1 6857388
33 Adjuvants, Immunologic Phase 4
34 Chelating Agents Phase 4
35 Benphothiamine Phase 4
36 diuretics Phase 4
37 Natriuretic Agents Phase 4
38 Nitric Oxide Donors Phase 4
39 isosorbide-5-mononitrate Phase 4
40 Angiotensinogen Phase 4
41 Giapreza Phase 4
42 Angiotensin Receptor Antagonists Phase 4
43 Trace Elements Phase 4
44 Micronutrients Phase 4
45 Vitamins Phase 4
46 Alpha-lipoic Acid Phase 4
47 Vitamin B9 Phase 4
48 Folate Phase 4
49 Vitamin B Complex Phase 4
50 Thioctic Acid Phase 4

Interventional clinical trials:

(show top 50) (show all 509)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Impact of Subject and Staff Training on the Pregabalin vs. Placebo Difference in Subjects With Painful Diabetic Neuropathy (PDN) Unknown status NCT01770964 Phase 4 Pregabalin;placebo
2 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial Unknown status NCT00123136 Phase 4
3 Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial Unknown status NCT00752440 Phase 4
4 Duloxetine as an Analgesic Agent in Patients Undergoing Elective Spine Surgery Unknown status NCT02535000 Phase 4 Duloxetine;Placebo
5 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
6 Effects of Pregabalin on Mechanical Hyperalgesia - EPOM Unknown status NCT00310583 Phase 4 Pregabalin
7 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus. Unknown status NCT02011620 Phase 4
8 Effects of a Chronical Treatment With Benfotiamine in People With Type 2 Diabetes Mellitus on Pre- and Postprandial Endothelial Function, as Well as on the Function of the Autonomic Nervous System Unknown status NCT00446810 Phase 4 Benfotiamine;Placebo
9 Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients With Diabetic Peripheral Neuropathic Pain Completed NCT00322621 Phase 4 Duloxetine
10 Training "Pain Connoisseurs" for Efficient Analgesic Proof-of-Concept Studies Completed NCT02842554 Phase 4 Drug Placebo Administration
11 An Open, Multicenter Study on the Efficacy, Safety and Tolerability of Gabapentin, Titrated for Reaching an Effect for the Treatment of the Painful Diabetic Neuropathy Completed NCT00644748 Phase 4 gabapentin
12 A Comparison of Strategies for Switching Patients From Amitriptyline to Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00266643 Phase 4 duloxetine hydrochloride
13 An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
14 A Prospective, Open-Label, Multicenter Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain Completed NCT00904020 Phase 4 Lidoderm
15 A 12-week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Clinical Trial to Compare the Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy Completed NCT03914404 Phase 4 γ-linoleic acid and placebo(Thioctic Acid);Thioctic Acid and placebo(γ-linoleic acid)
16 Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
17 Comparative Evaluation of Standard Wearing Shoes With Rocker Sole Shoes in Diabetic Patients With Neuropathy Completed NCT02891928 Phase 4
18 A Randomized, Double-Blind, Placebo-Controlled, Single Center Study Designed to Assess the Effects of Pregabalin on Change in Patients With Diabetic Neuropathy Completed NCT00573261 Phase 4 Pregabalin;Placebo
19 Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapy™ in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
20 A Phase IV Clinical Trial. Effect of Pulsing Electromagnetic Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
21 Comparison of the Effectiveness and Safety Between Tramadol 37.5 Mg/Acetaminophen 325mg And Gabapentin for The Treatment of Painful Diabetic Neuropathy: Multicenter, Randomized, Open Comparative Study Completed NCT00634543 Phase 4 Tramadol hydrochloride/ Acetaminophen;Gabapentin
22 An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus) Completed NCT00194909 Phase 4 sildenafil (Viagra)
23 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
24 Treatment With Alpha-lipoic Acid Over 16 Weeks in Type 2 Diabetic Patients With Symptomatic Polyneuropathy Who Responded to Initial 4-week High-dose Loading Completed NCT02439879 Phase 4 Alpha lipoic acid
25 Efficacy of Administration of Angiotensin Converting Enzyme Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
26 A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NCT00380913 Phase 4 Cesamet™ (nabilone)
27 A Randomized, Single-dose, Parallel-group Study to Evaluate the Pharmacokinetic Profiles of Two Formulation of Pregabalin in Healthy Volunteers Under Fasting Conditions Completed NCT03712475 Phase 4 Pregabalin
28 A Japan Post-Marketing, Randomized, Double-Blind, Parallel-Group, Flexible Dose Comparative Study to Assess the Non-Inferiority of Duloxetine Compared With Pregabalin in Patients With Diabetic Peripheral Neuropathic Pain Completed NCT02417935 Phase 4 Duloxetine;Pregabalin;Placebo
29 PRELIMINARY EVALUATION OF RETINAL EFFECTS OF PHARMACOLOLOGICAL LOWERING OF SERUM LEVES OF ADVANCED GLYCATION END-PRODUCTS (AGEs) IN TYPE 2 DIABETIC PATIENTS Completed NCT02249897 Phase 4 CHOLESTYRAMINE
30 A Prospective, Open Label, Multi-Center, Study Of Pregabalin In The Treatment Of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, HIV-Related Peripheral Neuropathic Pain And Chemotherapy Induced Peripheral Neuropathic Pain Completed NCT00407511 Phase 4 Pregabalin
31 A 24 Week, Double-blind, Placebo-controlled, Multisite Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
32 An Open-label, Randomized, Multi-center Clinical Trial to Evaluate the Safety and Efficacy in Peripheral Neuropathies Patients Treated With Mecobalamin Injection Completed NCT01192113 Phase 4 Mecobalamin IV Injection;Mecobalamin IM injection;Mecobalamin IV or IM injection
33 A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers Completed NCT01835379 Phase 4
34 Randomized Double Blind Placebo Controlled Multicenter Study of the Efficacy and Safety of Repeated Administrations of Botulinum Toxin Type A (Botox) in the Treatment of Peripheral Neuropathic Pain Completed NCT01251211 Phase 4 botulinum toxin type A
35 A Randomized, Double Blind, Placebo Controlled Prospective Study to Evaluate the Effectiveness of Monochromatic Infrared Photo Energy to Improve Diabetic Sensory Neuropathy Completed NCT00120341 Phase 4
36 A Randomised, Controlled, Cross-over Study With Inpatient and Outpatient Phases Completed NCT01352767 Phase 4
37 Open Labelled Study of Pregabalin in the Treatment of Neuropathic Pain in Cervical Myeloradiculopathy (Pregabalin and Radicular Pain Study (PARPS)) Completed NCT01061697 Phase 4 Pregabalin
38 Efficacy of Pregabalin in Patients With Radicular Pain Completed NCT00908375 Phase 4 Pregabalin;Sugar Pill
39 A Prospective, Open-label Trial of Lidoderm® (Lidocaine Patch 5%)in Painful Diabetic and Idiopathic Neuropathy. Completed NCT00903851 Phase 4 Lidoderm
40 Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain Completed NCT01364298 Phase 4 Gabapentin/B-complex;Pregabalin
41 Impact of Timed Bromocriptine-QR Therapy Upon Measures of Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects Completed NCT02682901 Phase 4 Cycloset;Placebo
42 A 12 Weeks Open Label Two Parallel Groups Study to Assess the Efficacy of Orally Administered Duloxetine 60 mg and 120 mg Per Day on Treatment Outcomes in Patients With Diabetic Peripheral Neuropathic Pain With and Without Co-morbid Major Depressive Disorder. The Primary Objective of This Study is to Evaluate Whether the Efficacy of Duloxetine Given as 60 mg to 120 mg Once Daily (QD), Measured by the BPI Interference Score After 12 Weeks Shows a Clinically Relevant Improvement in the DPNP Patients With Co-morbid MDD Completed NCT00844194 Phase 4 Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 90 mg QD;Duloxetine 90 mg QD;Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 120 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 120 mg QD
43 Dipeptidyl Peptidase (DPP) IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Patients With Type 2 Diabetes Completed NCT01472432 Phase 4 Placebo;vildagliptin
44 A Trial of Telmisartan Prevention of Cardiovascular Disease Completed NCT01075698 Phase 4 Non-ARB (standard therapy);ARB (Telmisartan)
45 L-Arginine and Endothelial Dysfunction in Type 2 Diabetic Patients Completed NCT00902616 Phase 4
46 Gabapentin Kinetic Disposition and Renal Excretion: Role of Transporters for Organic Cations and the Effect of Glycemic Control in Patients With Neuropathic Pain. Completed NCT03047278 Phase 4 Gabapentin 300 mg;Cetirizine Hydrochloride 10 mg
47 The Role of Lovaza® on Microvascular Function and Lipoprotein Profile in Type 2 Diabetes Completed NCT00931879 Phase 4 omega-3-ethyl esters;Placebo
48 An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Completed NCT00961298 Phase 4 Duloxetine
49 Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A Completed NCT01803828 Phase 4 Tadalafil;Placebo
50 Attenuation of Spinal Induced Hypotension With Granisetron in Type I Diabetic Parturients Recruiting NCT03091881 Phase 4 Granisetron 0.1 MG/ML;Placebos

Search NIH Clinical Center for Diabetic Neuropathy

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Becaplermin
CAPSACIAN PWDR
Capsaicin
CAPSAICIN PWDR
Capsicum extract
CAPSICUM OLEORESIN
Citalopram
Citalopram hydrobromide
COBALAMIN CONCENTRATE
Duloxetine
Hydroxocobalamin
HYDROXOCOBALAMIN ACETATE
mecobalamin
Mexiletine
Mexiletine Hydrochloride
Oxcarbazepine
Pentoxifylline
Pregabalin
Tapentadol
Vitamin B 12

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Diabetic Neuropathy cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Diabetic Neuropathy:
Hematopoietic stem cells for limb ischemia and diabetic neuropathy
Embryonic/Adult Cultured Cells Related to Diabetic Neuropathy:
Peripheral blood-derived hematopoietic stem cells (family)

Genetic Tests for Diabetic Neuropathy

Anatomical Context for Diabetic Neuropathy

MalaCards organs/tissues related to Diabetic Neuropathy:

41
Testes, Skin, Spinal Cord, Endothelial, Heart, Bone, Brain

Publications for Diabetic Neuropathy

Articles related to Diabetic Neuropathy:

(show top 50) (show all 6486)
# Title Authors PMID Year
1
Diabetic neuropathy research: from mouse models to targets for treatment. 38
31290436 2019
2
Cure of human diabetic neuropathy by HPLC validated bark extract of Onosma echioides L. root. 38
29629826 2019
3
New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism. 38
31346658 2019
4
Clinical features and burden of new onset diabetic foot ulcers post simultaneous pancreas kidney transplantation and kidney only transplantation. 38
31301954 2019
5
A review on protective role of genistein against oxidative stress in diabetes and related complications. 38
31125535 2019
6
The natural plant flavonoid apigenin is a strong antioxidant that effectively delays peripheral neurodegenerative processes. 38
30949912 2019
7
Acupuncture for painful diabetic neuropathy. 38
31433572 2019
8
Spinal Serotonin and 5HT6 Receptor Levels During Development of Neuropathy and Influence of Blockade of these Receptors on Thermal Hyperalgesia in Diabetic Mice. 38
30609433 2019
9
Eruca sativa Meal against Diabetic Neuropathic Pain: An H2S-Mediated Effect of Glucoerucin. 38
31430978 2019
10
Anxiety, depression and sleep disorders in patients with diabetic neuropathic pain: a systematic review. 38
31393191 2019
11
Oxidative stress markers in cognitively intact patients with diabetic neuropathy. 38
31175898 2019
12
Awareness of diabetes and diabetic retinopathy among a group of diabetic patients in main public hospitals in Damascus, Syria during the Syrian crisis. 38
31382956 2019
13
Burden of hereditary transthyretin amyloidosis on quality of life. 38
31093980 2019
14
A rare case of a gabapentin-induced cardiomyopathy. 38
30968430 2019
15
Peripheral Neuropathy as a Component of Skeletal Disease in Diabetes. 38
31392667 2019
16
Dyshidrosis associated with diabetes mellitus: Hypohidrosis associated with diabetic neuropathy and compensated hyperhidrosis. 38
30859595 2019
17
Physical activity and dietary interventions in diabetic neuropathy: a systematic review. 38
31076938 2019
18
Augmented corneal nerve fiber branching in painful compared to painless diabetic neuropathy. 38
31390004 2019
19
Medical complications associated with substance use disorders in patients with type 2 diabetes and hypertension: electronic health record findings. 38
30851217 2019
20
The selective TRPV4 channel antagonist HC-067047 attenuates mechanical allodynia in diabetic mice. 38
31129158 2019
21
Central Corneal Thickness can be Related to Diabetic Peripheral Neuropathy in Children with Type 1 Diabetes. 38
31412377 2019
22
Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test. 38
31172429 2019
23
CXCL13/CXCR5 signaling contributes to diabetes-induced tactile allodynia via activating pERK, pSTAT3, pAKT pathways and pro-inflammatory cytokines production in the spinal cord of male mice. 38
31100371 2019
24
Sonographic assessment of nerve blood flow in diabetic neuropathy. 38
31338857 2019
25
Polyphenols for diabetes associated neuropathy: Pharmacological targets and clinical perspective. 38
31352568 2019
26
Cav-1 participates in the development of diabetic neuropathy pain through the TLR4 signaling pathway. 38
31318049 2019
27
Nesfatin-1 protects PC12 cells against high glucose-induced cytotoxicity via inhibiting oxidative stress, autophagy and apoptosis. 38
31323241 2019
28
Between visit variability of thermal imaging of feet in people attending podiatric clinics with diabetic neuropathy at high risk of developing foot ulcers. 38
31362275 2019
29
The effect of exercise therapy combined with psychological therapy on physical activity and quality of life in patients with painful diabetic neuropathy: a systematic review. 38
31112511 2019
30
Plant-derived medicines for neuropathies: a comprehensive review of clinical evidence. 38
30768427 2019
31
Spinal cord stimulation: Beyond pain management. 38
31337556 2019
32
Ameliorative Effect of Berberine on Neonatally Induced Type 2 Diabetic Neuropathy via Modulation of BDNF, IGF-1, PPAR-γ, and AMPK Expressions. 38
31360147 2019
33
Liraglutide treatment reduced interleukin 6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy. 38
31338868 2019
34
Methylglyoxal and a spinal TRPA1-AC1-Epac cascade facilitate pain in the db/db mouse model of type 2 diabetes. 38
30807826 2019
35
Factors associated with diabetic polyneuropathy-related sensory symptoms and signs in patients with polyneuropathy: A cross-sectional Japanese study (JDDM 52) using a non-linear model. 38
31314173 2019
36
Nitric oxide modulates μ-opioid receptor function in vitro. 38
30933370 2019
37
Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. 38
31345776 2019
38
Low level laser therapy for the patients with painful diabetic peripheral neuropathy - A systematic review. 38
31405692 2019
39
Metformin reduces c-Fos and ATF3 expression in the dorsal root ganglia and protects against oxaliplatin-induced peripheral sensory neuropathy in mice. 38
31325582 2019
40
Associations of Serum S100B and S100P With the Presence and Classification of Diabetic Peripheral Neuropathy in Adults With Type 2 Diabetes: A Case-Cohort Study. 38
30872108 2019
41
Perineural Platelet-Rich Plasma for Diabetic Neuropathic Pain, Could It Make a Difference? 38
31298289 2019
42
Validation of Neuropad in the assessment of peripheral diabetic neuropathy in patients with Diabetes Mellitus versus the Michigan Neuropathy Screening Instrument, 10 g Monofilament application and Biothesiometer measurement. 38
31340739 2019
43
RANKL Gene Polymorphism as a Potential Biomarker to Identify Acute Charcot Foot Among Indian Population With Type 2 Diabetes: A Preliminary Report. 38
31304802 2019
44
Intravenous lidocaine in the management of chronic peripheral neuropathic pain: a randomized-controlled trial. 38
31098961 2019
45
Cannabidiol attenuates mechanical allodynia in streptozotocin-induced diabetic rats via serotonergic system activation through 5-HT1A receptors. 38
30898678 2019
46
Raman spectroscopy of dorsal root ganglia from streptozotocin-induced diabetic neuropathic rats submitted to photobiomodulation therapy. 38
31265175 2019
47
Purification and biochemical characterisation of a putative sodium channel agonist secreted from the South African Knobbly sea anemone Bunodosoma capense. 38
31330191 2019
48
Tracking Pain in Resting State Networks in Patients with Hereditary and Diabetic Neuropathy. 38
31223239 2019
49
Endoplasmic reticulum mitochondria contacts modulate apoptosis of renal cells and its implications in diabetic neuropathy. 38
31201142 2019
50
Effects of adipose derived stromal vascular fraction on diabetic neuropathy: an experimental study. 38
31240978 2019

Variations for Diabetic Neuropathy

Expression for Diabetic Neuropathy

Search GEO for disease gene expression data for Diabetic Neuropathy.

Pathways for Diabetic Neuropathy

Pathways related to Diabetic Neuropathy according to KEGG:

37
# Name Kegg Source Accession
1 AGE-RAGE signaling pathway in diabetic complications hsa04933

Pathways related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.84 PRKCB NTRK1 NTF3 NGF INS ACE
2
Show member pathways
12.75 VEGFA NTRK1 NTF3 NGF INS EPO
3 12.47 VEGFA PRKCB NTRK1 NTF3 NGF INS
4
Show member pathways
12.38 VEGFA PRKCB NTRK1 NTF3 NGF INS
5
Show member pathways
12.22 VEGFA TRPV1 PRKCB PARP1 NTRK1 NGF
6 11.71 VEGFA PRKCB AGER
7 11.71 VEGFA PRKCB INS EPO
8 11.49 PRKCB INS AGER
9
Show member pathways
11.42 NTRK1 NTF3 NGF
10 11.23 NTRK1 NTF3 NGF
11 11.15 VEGFA NTF3 NGF CNTF
12 11.12 PRKCB PARP1 INS
13 10.61 VEGFA INS EPO CNTF
14
Show member pathways
10.55 NTRK1 NGF

GO Terms for Diabetic Neuropathy

Cellular components related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 VEGFA NTF3 NGF INS EPO CNTF
2 extracellular space GO:0005615 9.61 VEGFA NTF3 NGF INS EPO CNTF
3 axon GO:0030424 9.02 SCN9A NTRK1 NTF3 NGF CNTF

Biological processes related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.99 VEGFA NTF3 INS EPO CNTF
2 positive regulation of cell migration GO:0030335 9.87 VEGFA SOD2 NTF3 INS
3 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.79 NTRK1 NTF3 NGF
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.78 PRKCB NTRK1 INS AGER
5 activation of protein kinase activity GO:0032147 9.77 VEGFA EPO CALCA
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 VEGFA EPO CNTF
7 regulation of blood pressure GO:0008217 9.72 SOD2 CALCA ACE
8 sensory perception of pain GO:0019233 9.71 TRPV1 SCN9A NTRK1
9 negative regulation of apoptotic process GO:0043066 9.7 VEGFA NTRK1 NGF MPZ GLO1 EPO
10 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.62 VEGFA PRKCB
11 macrophage differentiation GO:0030225 9.62 VEGFA PARP1
12 nerve development GO:0021675 9.61 NTF3 NGF
13 cellular response to amyloid-beta GO:1904646 9.61 PARP1 NTRK1 AGER
14 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.58 SOD2 INS
15 behavioral response to pain GO:0048266 9.58 TRPV1 SCN9A
16 peripheral nervous system development GO:0007422 9.58 PMP22 NTF3 NGF
17 positive regulation of Ras protein signal transduction GO:0046579 9.54 NTRK1 NGF EPO
18 aging GO:0007568 9.52 NTRK1 EPO
19 negative regulation of calcium ion transport into cytosol GO:0010523 9.51 EPO CALCA
20 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.49 VEGFA ACE
21 cellular response to nerve growth factor stimulus GO:1990090 9.46 TRPV1 NTRK1
22 induction of positive chemotaxis GO:0050930 9.43 VEGFA NTF3 AGER
23 detection of temperature stimulus involved in sensory perception of pain GO:0050965 9.32 TRPV1 NTRK1
24 nerve growth factor signaling pathway GO:0038180 9.13 NTRK1 NTF3 NGF
25 negative regulation of neuron apoptotic process GO:0043524 9.02 SOD2 NTRK1 NTF3 NGF CNTF

Molecular functions related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.5 VEGFA TRPV1 SOD2 PARP1 INS CALCA
2 hormone activity GO:0005179 9.33 INS EPO CALCA
3 growth factor activity GO:0008083 8.92 VEGFA NTF3 NGF CNTF

Sources for Diabetic Neuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....